{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:25:57Z","timestamp":1723767957192},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1707","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved daxibotulinumtoxinA-lanm (Daxxify \u2013 Revance), an acetylcholine release inhibitor and neuromuscular blocking agent, for temporary improvement in the appearance of moderate to severe glabellar (frown) lines associated with corrugator and\/or procerus muscle activity. Daxxify is the fifth botulinumtoxin type A product to be approved in the US for this indication. It is also approved for treatment of cervical dystonia in adults.<\/jats:p>","DOI":"10.58347\/tml.2024.1707g","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:29:33Z","timestamp":1723735773000},"page":"e121-e122","source":"Crossref","is-referenced-by-count":0,"title":["DaxibotulinumtoxinA (Daxxify) for Frown Lines"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,7,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:29:33Z","timestamp":1723735773000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1707g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":0,"journal-issue":{"issue":"1707","published-online":{"date-parts":[[2024,7,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1707g","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}